Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/129280
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | NLRP3 inflammasome is activated in fibromyalgia: The effect of coenzyme Q10 |
Autor: | Cordero, Mario D. CSIC ORCID; Alcocer-Gómez, Elísabet; Carrión Rodríguez, Ángel Manuel CSIC ORCID; Miguel, Manuel de; Díaz, Eduardo CSIC ORCID ; Bullón, Pedro CSIC ORCID; Battino, Maurizio; Sánchez-Alcázar, José Antonio CSIC ORCID | Fecha de publicación: | 2014 | Editor: | Mary Ann Liebert | Citación: | Antioxidants and Redox Signaling 20(8): 1169-1180 (2014) | Resumen: | [Aims]: Fibromyalgia (FM) is a prevalent chronic pain syndrome characterized by generalized hyperalgesia associated with a wide spectrum of symptoms such as fatigue and joint stiffness. Diagnosis of FM is difficult due to the lack of reliable diagnostic biomarkers, while treatment is largely inadequate. We have investigated the role of coenzyme Q10 (CoQ10) deficiency and mitochondrial dysfunction in inflammasome activation in blood cells from FM patients, and in vitro and in vivo CoQ10 deficiency models. [Results]: Mitochondrial dysfunction was accompanied by increased protein expression of interleukin (IL)-1ß, NLRP3 (NOD-like receptor family, pyrin domain containing 3) and caspase-1 activation, and an increase of serum levels of proinflammatory cytokines (IL-1ß and IL-18). CoQ10 deficiency induced by p-aminobenzoate treatment in blood mononuclear cells and mice showed NLRP3 inflammasome activation with marked algesia. A placebo-controlled trial of CoQ10 in FM patients has shown a reduced NLRP3 inflammasome activation and IL-1ß and IL-18 serum levels. [Innovation]: These results show an important role for the NLRP3 inflammasome in the pathogenesis of FM, and the capacity of CoQ10 in the control of inflammasome. Conclusion: These findings provide new insights into the pathogenesis of FM and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease. | URI: | http://hdl.handle.net/10261/129280 | DOI: | 10.1089/ars.2013.5198 | Identificadores: | doi: 10.1089/ars.2013.5198 issn: 1523-0864 e-issn: 1557-7716 |
Aparece en las colecciones: | (CABD) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
39
checked on 02-mar-2024
SCOPUSTM
Citations
75
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
72
checked on 23-feb-2024
Page view(s)
285
checked on 23-abr-2024
Download(s)
72
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.